A study finds direct evidence to support guideline changes that promote lower targets for low-density lipoprotein cholesterol ...

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

ApoB goal optimal in 65% of probabilistic analyses at willingness-to-pay threshold of $120,000 per QALY gained.

Modern medicine is improving in precision, identifying exactly who needs treatment and who doesn’t. In heart disease ...

What happens when this doctor goes keto and his LDL rockets to 574? We dive deep into the science, controversy, and personal ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third ...